Follow us...

 

Search News Archives

News Channels

 

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

Avacta Group plc Announces Positive Outcome of Proof-of-Concept Study with Glythera and Follow-on Drug Development Partnership

publication date: Jan 25, 2018
 | 
author/source: Avacta Life Sciences

avactaAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully. 

Following this study the two companies have agreed the terms of a licensing deal which will allow them to develop drug conjugates using the combined technologies.  The detailed terms of the license have not been disclosed but Avacta would receive development milestone payments and royalties on sales of an approved drug developed by Glythera.

The antibody drug conjugate market is estimated to be worth around $1bn today from two approved compounds and is expected to be worth $14.6bn annually by 20301.  Drug conjugates combine a chemotherapy (toxin) with a protein such as an antibody or Affimer to target that toxin to the tumor.

Avacta and Glythera have carried out a proof-of-concept study designed to demonstrate that Avacta’s Affimer® technology could be combined with Glythera’s Permalink® conjugation chemistry to provide a technically superior drug conjugate platform with shorter development times, simpler, more consistent production and greater chemical stability.  An Affimer, compared with a much larger antibody, potentially also allows greater control over the time the drug spends in the blood stream and deeper tumor penetration producing a more effective medicine with fewer toxic side effects.

Importantly, the initial trial has also shown that the Affimer remains functional when the toxic payload has been added indicating that the combination of the two technologies has the potential to develop drug conjugate therapies.

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented: “The drug conjugate market is a very important one for the Affimer technology because of the key benefits of Affimers’ solvent stability, controlled conjugation chemistry and small size which have now been clearly demonstrated.  When combined with the benefits of Glythera’s Permalink chemistry, we believe that there is potential to create a competitive, differentiated drug conjugate platform.

I am delighted with the reciprocal arrangements that we have put in place with Glythera allowing both companies to develop Affimer-Permalink drug conjugates and I look forward to updating the market on progress in Avacta’s drug development programmes in due course.”


more about avacta


more news from avacta


 


If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners